EVM
NBIX icon

Eaton Vance Management’s Neurocrine Biosciences NBIX Stock Holding History

Eaton Vance Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$143M Sell
1,347,820
-121,797
-8% -$12.4M 0.21% 99
2022
Q2 		$143M Buy
1,469,617
+13,569
+0.9% +$1.25M 0.2% 107
2022
Q1 		$137M Sell
1,456,048
-390,867
-21% -$33.1M 0.16% 138
2021
Q4 		$157M Sell
1,846,915
-38,991
-2% -$3.59M 0.19% 109
2021
Q3 		$181M Buy
1,885,906
+652,772
+53% +$61.7M 0.25% 84
2021
Q2 		$120M Buy
1,233,134
+416,718
+51% +$39.9M 0.16% 132
2021
Q1 		$79.4M Buy
816,416
+287,927
+54% +$30.2M 0.12% 182
2020
Q4 		$50.7M Buy
528,489
+399,834
+311% +$38.6M 0.08% 236
2020
Q3 		$12.4M Hold
128,655
– – 0.02% 442
2020
Q2 		$15.7M Hold
128,655
– – 0.03% 370
2020
Q1 		$11.1M Buy
128,655
+10,634
+9% +$1.04M 0.03% 392
2019
Q4 		$12.7M Sell
118,021
-16,007
-12% -$1.68M 0.02% 414
2019
Q3 		$12.1M Hold
134,028
– – 0.03% 406
2019
Q2 		$11.3M Sell
134,028
-28,973
-18% -$2.38M 0.02% 407
2019
Q1 		$14.4M Buy
163,001
+33,567
+26% +$2.81M 0.03% 344
2018
Q4 		$9.24M Buy
129,434
+22,280
+21% +$2.13M 0.02% 380
2018
Q3 		$13.2M Buy
107,154
+27,331
+34% +$3.1M 0.03% 362
2018
Q2 		$7.84M Sell
79,823
-29,125
-27% -$2.61M 0.02% 437
2018
Q1 		$9.04M Buy
108,948
+88,948
+445% +$7.51M 0.01% 532
2017
Q4 		$1.55M Buy
+20,000
New +$1.36M ﹤0.01% 752

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eaton Vance Management's NBIX Position: Q3 2022 in Review

Eaton Vance Management reduced its Neurocrine Biosciences (NBIX) stake by 8.3% in Q3 2022, selling an estimated $12.4M and leaving 1,347,820 shares worth $143M. The position accounts for 0.21% of the portfolio, ranked #99.

Eaton Vance Management first reported a position in NBIX in Q4 2017 and has held it in 20 quarters since. The position peaked at $181M in Q3 2021. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Eaton Vance Management held 1,347,820 shares of Neurocrine Biosciences worth $143M as of Q3 2022.
  • Eaton Vance Management sold 121,797 Neurocrine Biosciences shares in Q3 2022, an estimated $12.4M.
  • Neurocrine Biosciences made up 0.21% of Eaton Vance Management's portfolio in Q3 2022, its #99 holding.
  • Eaton Vance Management first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 20 quarters since.
  • Eaton Vance Management's Neurocrine Biosciences position peaked at $181M in Q3 2021.
  • 466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.